

People recently diagnosed with Type 2 diabetes are at higher risk for developing pancreatic cancer. Bluestar Genomics is studying a new blood test to identify pancreatic cancer in people with recently diagnosed Type 2 diabetes.

You may be a candidate for this research study if the following apply:

- You are 50 years of age or older
- You've recently been diagnosed with Type 2 diabetes within 6 months



Type 2 diabetes and pancreatic cancer:

What is the connection and why is early detection of pancreatic cancer important?

Most people aren't aware that those recently diagnosed with Type 2 diabetes are at higher risk for pancreatic cancer.

Although pancreatic cancer is rare even among people with Type 2 diabetes, accounting for only 3% of new cancer cases, it is the third leading cause of cancer death in the United States. This is in part because it is often diagnosed too late for patients to receive effective treatments.

Bluestar Genomics has developed a noninvasive epigenomic test that can detect pancreatic cancer through a standard blood draw, helping clinicians to detect the disease signal sooner when patients have more treatment options.



About the Bluestar Genomics study


This new pancreatic cancer test uses a standard blood draw to assess whether an individual has an abnormal DNA signal associated with pancreatic cancer.

In the Bluestar Genomics study, you may undergo up to two blood draws: one at the time of enrollment; one six months after your Type 2 diabetes diagnosis.

As a follow up to FDA's Breakthrough Device Designation for this test, the purpose of the study is to validate the test's ability to rule out pancreatic cancer in people with Type 2 diabetes at that time.

How does this clinical trial work?

If the test detects a positive signal (meaning your blood shows epigenetic signals consistent with pancreatic cancer), you will be directed to get an MRI to look for possible abnormalities in your pancreas. Based on the results of the MRI, follow-up testing and evaluation may be required to confirm the absence of abnormalities in the pancreas.



How can I learn more about participating in the clinical trial?

A clinical trial coordinator will contact you to discuss the trial in more detail, answer your questions and confirm your eligibility. If you choose to participate, a stipend will be offered to cover local transportation costs associated with traveling to the testing site.

Annapolis Internal Medicine
116 Defense Hwy. Ste. 400, Annapolis, MD 21401
Call 410-824-1005
Email: kerenmoore@cctresearch.com

<https://www.bluestargenomics.com/clinical-trials/>

How can I learn more about this research and resources in this area?

**LUSTGARTEN
FOUNDATION**
PANCREATIC CANCER RESEARCH

**PANCREATIC
CANCER
ACTION
NETWORK**
pancan.org®